Show simple item record

dc.contributor.authorSeverino, Patricia
dc.contributor.authorClares Naveros, Beatriz 
dc.date.accessioned2023-01-24T07:46:55Z
dc.date.available2023-01-24T07:46:55Z
dc.date.issued2022-10-17
dc.identifier.citationSeverino, P... [et al.]. Cutaneous/Mucocutaneous Leishmaniasis Treatment forWound Healing: Classical versus New Treatment Approaches. Microbiol. Res. 2022, 13, 836–852. [https://doi.org/10.3390/microbiolres13040059]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/79281
dc.description.abstractCutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (ML) show clinical spectra that can range from a localized lesion (with a spontaneous healing process) to cases that progress to a generalized systemic disease with a risk of death. The treatment of leishmaniasis is complex since most of the available drugs show high toxicity. The development of an effective topical drug formulation for CL and ML treatment offers advantages as it will improve patient’s compliance to the therapy given the possibility for self-administration, as well as overcoming the first pass metabolism and the high costs of currently available alternatives. The most common dosage forms include solid formulations, such as membranes and semi-solid formulations (e.g., ointments, creams, gels, and pastes). Topical treatment has been used as a new route of administration for conventional drugs against leishmaniasis and its combinations, as well as to exploit new substances. In this review, we discuss the advantages and limitations of using topical drug delivery for the treatment of these two forms of leishmaniasis and the relevance of combining this approach with other pharmaceutical dosage forms. Emphasis will also be given to the use of nanomaterials for site-specific delivery.es_ES
dc.description.sponsorshipCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)es_ES
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado do Sergipe (FAPITEC) 88887.159533/2017-00es_ES
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) CNPq 301964/2019-0 01/2019 06/2019es_ES
dc.description.sponsorshipFundacao Carolinaes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCutaneous leishmaniasis (CL)es_ES
dc.subjectMucocutaneous leishmaniasis (ML)es_ES
dc.subjectTopical formulationses_ES
dc.subjectDrug deliveryes_ES
dc.subjectNanomaterialses_ES
dc.titleCutaneous/Mucocutaneous Leishmaniasis Treatment for Wound Healing: Classical versus New Treatment Approacheses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/microbiolres13040059
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional